Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
74 75 Next >
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
The company has growing pipeline optionality, according to the upgrade report. 
Via Investor's Business Daily
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
7 Innovator Stocks Primed for Exceptional Growth
These featured, inventive companies are not only transforming old sectors but also building bridges toward new ones. 
Via InvestorPlace
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday
Express Scripts will give its clients access to Lexicon's first approved therapy. 
Via The Motley Fool
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For October 06
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For September 27
Via Benzinga
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near... 
Via Benzinga
Why Shares of Tango Therapeutics Are Dropping Monday
Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)
From Brodsky & Smith LLC
Via GlobeNewswire
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. 
Via Investor's Business Daily
Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total  
Via Benzinga
S&P 500, Nasdaq Set For Bleak Start To Week As Middle East Tensions Dampen Risk-On Mood: Earnings, Inflation Data In Focus
Trading in stock futures suggests a lower open on Monday as traders digest the ramification of the conflict in the Middle East. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
From Bristol Myers Squibb
Via Business Wire
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Potential approvals of new medicines expected soon could push these stocks through the roof. 
Via The Motley Fool
Thinking Of Buying Alexandria Real Estate Equities? Here Are The Properties And Tenants You'd Add To Your Portfolio
Via Benzinga
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Current Analysis: Bristol-Myers Squibb
Over the past year, Bristol’s share price dropped about 20.3% from $71.21 to $56.73 as of Wednesday’s market close. 
Via Talk Markets
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
The stars are aligning for these pharmaceutical giants, making their stocks look ready to run higher in next year. 
Via InvestorPlace
Medicare Drug Price Negotiation - What Court's Decision Means for Americans
A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices. 
Via Benzinga
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation 
Via Benzinga
3 Dividend Stocks to Buy and Hold Until Retirement
Together, these stocks can also help diversify your portfolio by giving you exposure to different industries. 
Via The Motley Fool
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
From Bristol Myers Squibb
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
These three healthcare stocks to sell are waving red flags at investors who should pay attention or suffer the consequences. 
Via InvestorPlace
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.